Pillar 1 - FTO (new thread), page-18

Another partnership, pre-clinical (early Phase I). In PD-I blockade space.

https://www.bioworld.com/articles/5...as-cancer-tie-up-with-biond-valued-at-1b-plus

cancer prospect BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors

• Israel-based Biotech ( so ... partnerships do happen for companies outside the US )
• IND filed for Phase I trial planned to start in 2021.
• USD $125M upfront
• + USD $1B in milestones
• Tiered double-digit royalties

From

https://www.prnewswire.com/news-rel...or-targeting-the-ilt2-receptor-301206200.html

Biond will lead the first-in-human, phase 1a study of BND-22, evaluating its safety and tolerability as a single agent and in combination with approved cancer therapeutics as well as exploring potential associations between BND-22 anti-tumor activity and select tumor and blood-based biomarkers; Sanofi will assume clinical development and commercialization responsibilities thereafter.

So the approach of identifying Biomarkers is similar to what RACE is doing for FTO. So I guess the above validates RACE's strategy.